Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Use of pairwise marker combination and recursive partitioning in a pharmacogenetic genome-wide scan.

Warren LL, Hughes AR, Lai EH, Zaykin DV, Haneline SA, Bansal AT, Wooster AW, Spreen WR, Hernandez JE, Scott TR, Roses AD, Mosteller M; CNA30027 and CNA30032 study teams..

Pharmacogenomics J. 2007 Jun;7(3):180-9.

PMID:
16969363
2.

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.

Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B, Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips D, Mallal S, Shaefer M; Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team..

Clin Infect Dis. 2008 Apr 1;46(7):1111-8. doi: 10.1086/529382.

PMID:
18444831
3.

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations.

Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH, Nangle K, Scott T, Spreen WR, Warren LL, Roses AD; CNA30027 Study Team.; CNA30032 Study Team..

Pharmacogenomics. 2004 Mar;5(2):203-11.

PMID:
15016610
4.

Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.

Guo Y, Shi L, Hong H, Su Z, Fuscoe J, Ning B.

Sci China Life Sci. 2013 Feb;56(2):119-24. doi: 10.1007/s11427-013-4438-8. Review. Erratum in: Sci China Life Sci. 2013 Mar;56(3):292.

PMID:
23393027
5.
6.

Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.

Hughes AR, Brothers CH, Mosteller M, Spreen WR, Burns DK.

Pharmacogenomics. 2009 Feb;10(2):225-33. doi: 10.2217/14622416.10.2.225. Review.

PMID:
19207023
7.

Abacavir pharmacogenetics--from initial reports to standard of care.

Martin MA, Kroetz DL.

Pharmacotherapy. 2013 Jul;33(7):765-75. doi: 10.1002/phar.1278. Review.

8.

Abacavir hypersensitivity reaction: an update.

Hughes CA, Foisy MM, Dewhurst N, Higgins N, Robinson L, Kelly DV, Lechelt KE.

Ann Pharmacother. 2008 Mar;42(3):387-96. doi: 10.1345/aph.1K522. Review.

PMID:
18303141
9.

HLA-B*5701 screening for hypersensitivity to abacavir.

Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A; PREDICT-1 Study Team..

N Engl J Med. 2008 Feb 7;358(6):568-79. doi: 10.1056/NEJMoa0706135.

10.

[Prospective validation of a pharmacogenetic test: the PREDICT-1 study].

Muñoz de Benito RM, Arribas López JR.

Enferm Infecc Microbiol Clin. 2008 May;26 Suppl 6:40-4. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2008 Oct;26(8):536.

PMID:
18680695
11.

Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.

Hughes AR, Spreen WR, Mosteller M, Warren LL, Lai EH, Brothers CH, Cox C, Nelsen AJ, Hughes S, Thorborn DE, Stancil B, Hetherington SV, Burns DK, Roses AD.

Pharmacogenomics J. 2008 Dec;8(6):365-74. doi: 10.1038/tpj.2008.3. Review.

PMID:
18332899
12.

Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos.

Sanchez-Giron F, Villegas-Torres B, Jaramillo-Villafuerte K, Silva-Zolezzi I, Fernandez-Lopez JC, Jimenez-Sanchez G, Carnevale A.

Pharmacogenomics. 2011 Jun;12(6):809-14. doi: 10.2217/pgs.11.31.

PMID:
21510768
13.

Abacavir hypersensitivity: a model system for pharmacogenetic test adoption.

Lai-Goldman M, Faruki H.

Genet Med. 2008 Dec;10(12):874-8. doi: 10.1097/GIM.0b013e31818de71c. Review.

PMID:
19092439
14.

Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.

Berka N, Gill JM, Liacini A, O'Bryan T, Khan FM.

Hum Immunol. 2012 Feb;73(2):164-7. doi: 10.1016/j.humimm.2011.12.002.

PMID:
22197535
15.

Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.

Giorgini S, Martinelli C, Tognetti L, Carocci A, Giuntini R, Mastronardi V, Torricelli F, Leoncini F, Lotti T.

Dermatol Ther. 2011 Nov-Dec;24(6):591-4. doi: 10.1111/j.1529-8019.2012.01409.x.

PMID:
22515676
16.

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond LM, Roses AD.

Lancet. 2002 Mar 30;359(9312):1121-2.

PMID:
11943262
17.

The frequency of HLA-B(∗)57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica.

Arrieta-Bolaños E, Madrigal JA, Marsh SG, Shaw BE, Salazar-Sánchez L.

Hum Immunol. 2014 Nov;75(11):1092-6. doi: 10.1016/j.humimm.2014.09.011.

PMID:
25286002
18.

Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions.

Nelson MR, Bacanu SA, Mosteller M, Li L, Bowman CE, Roses AD, Lai EH, Ehm MG.

Pharmacogenomics J. 2009 Feb;9(1):23-33. doi: 10.1038/tpj.2008.4.

PMID:
18301416
19.

A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.

Martin AM, Krueger R, Almeida CA, Nolan D, Phillips E, Mallal S.

Pharmacogenet Genomics. 2006 May;16(5):353-7.

PMID:
16609367
20.

Successful translation of pharmacogenetics into the clinic: the abacavir example.

Phillips E, Mallal S.

Mol Diagn Ther. 2009;13(1):1-9. doi: 10.2165/01250444-200913010-00001. Review.

PMID:
19351209

Supplemental Content

Support Center